Related Experiment Video

Updated: Aug 29, 2025

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

24.6K

Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review

Tiago Aguiar1, Elisabete Martins2

  • 1Faculty of Medicine, University of Porto, Porto, Portugal.

Revista Portuguesa De Cardiologia : Orgao Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology
|September 8, 2022
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease. This review covers current HCM diagnosis and management, highlighting mavacamten, a novel cardiac myosin inhibitor, for potential future treatment.

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac condition.
  • Characterized by left ventricular wall thickness ≥15 mm without other causes.
  • Obstructive hypertrophic cardiomyopathy (oHCM) affects up to 75% of patients, causing left ventricular outflow tract obstruction.

Purpose of the Study:

  • To provide an overview of contemporary HCM diagnosis and management.
  • To review the novel therapeutic agent mavacamten, a cardiac myosin inhibitor.
  • To anticipate the future impact of mavacamten on HCM treatment algorithms.

Main Methods:

  • Review of current literature on hypertrophic cardiomyopathy.
  • Analysis of diagnostic criteria and current therapeutic strategies for HCM.
  • Integration of emerging data on mavacamten's mechanism and clinical potential.

Main Results:

  • Current treatments for symptomatic obstructive HCM include empirical pharmacological therapy, surgery, alcohol ablation, and pacing.
  • Mavacamten represents a first-in-class allosteric inhibitor targeting cardiac myosin.
  • Mavacamten offers a potential targeted therapy for HCM patients.

Conclusions:

  • HCM management requires a comprehensive approach to diagnosis and symptom control.
  • Mavacamten shows promise as a targeted therapy, potentially altering future treatment paradigms for HCM.
  • Further research and clinical integration of mavacamten are anticipated.

Keywords:
Hypertrophic cardiomyopathyLeft ventricular outflow obstructionMYK-461Miocardiopatia hipertróficaObstrução do trato de saída do ventrículo esquerdo

More Related Videos

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

3.8K
Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction08:35

Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction

Published on: August 17, 2022

2.5K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
38
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
29
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
22
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
42
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
18